Phillip L. Palmbos

Phillip L. Palmbos

Oncology | Hematology

1500 E Medical Center Dr
Floor B1 Reception E
Ann Arbor, MI 48109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.

Journal: bioRxiv : the preprint server for biology

Published: July 30, 2026

TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.

TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.

Journal: Research square

Published: June 04, 2026

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

Journal: European urology

Published: September 26, 2025

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Journal: JCO precision oncology

Published: September 16, 2025

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.

Journal: Future oncology (London, England)

Published: September 01, 2025

Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma.

Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma.

Journal: Clinical genitourinary cancer

Published: July 29, 2025

The molecular mechanism of ambrosin-induced cytotoxicity of human breast cancer and bladder cancer cells.

The molecular mechanism of ambrosin-induced cytotoxicity of human breast cancer and bladder cancer cells.

Journal: The Journal of biological chemistry

Published: April 22, 2025

Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.

Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.

Journal: Urology practice

Published: October 09, 2024

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 26, 2024

Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics.

Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics.

Journal: Neoplasia (New York, N.Y.)

Published: June 07, 2024

A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.

A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.

Journal: Future oncology (London, England)

Published: April 29, 2024

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 04, 2024

Showing 1-12 of 39

Last Updated: 09/26/2026